Globe Newswire (Fri, 27-Mar 5:00 AM ET)
Globe Newswire (Tue, 24-Mar 3:26 AM ET)
Globe Newswire (Fri, 13-Mar 5:00 AM ET)
Globe Newswire (Fri, 27-Feb 4:00 AM ET)
Genenta’s Bold Shift: Strategic Transformation and Defense Sector Expansion Signal New Era for GNTA
Market Chameleon (Tue, 27-Jan 4:53 AM ET)
Globe Newswire (Tue, 27-Jan 3:00 AM ET)
Market Chameleon (Fri, 24-Oct 5:52 AM ET)
Market Chameleon (Fri, 24-Oct 3:05 AM ET)
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
Genenta Science S.P.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GNTA.
As of April 22, 2026, GNTA stock price was flat at $0.69 with 4,424 million shares trading.
GNTA has a beta of 1.91, meaning it tends to be more sensitive to market movements. GNTA has a correlation of 0.04 to the broad based SPY ETF.
GNTA has a market cap of $16.17 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GNTA traded as high as $10.00 and as low as $.59.
GNTA has underperformed the market in the last year with a price return of -82.2% while the SPY ETF gained +39.6%. GNTA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.7% and -0.4%, respectively, while the SPY returned +3.8% and +7.7%, respectively.
GNTA support price is $.63 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNTA shares will trade within this expected range on the day.
